Protara (TARA) Chief R&D Officer sells 22,598 shares under 10b5-1 plan

Rhea-AI Filing Summary

Protara Therapeutics Chief R&D Officer sells shares under trading plan. Jacqueline Zummo completed an open-market sale of 22,598 shares of Protara Therapeutics common stock at a weighted average price of $5.26 per share. After this automatic sale under a Rule 10b5-1 trading plan established on December 31, 2025, she directly holds 95,961 shares.

Insider Trade Summary

Net Seller: 22,598 shares ($118,865)

Net Sell 1 txn

Insider Zummo Jacqueline

Role Chief R&D Officer

Sold 22,598 shs ($119K)

Type	Security	Shares	Price	Value
Sale	Common Stock	22,598	$5.26	$119K

Holdings After Transaction: Common Stock — 95,961 shares (Direct)

Footnotes (1)

1. The sale reported on this Form 4 occurred automatically pursuant to a Rule 10b5-1 trading plan established by the reporting person on December 31, 2025. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $5.25 to $5.31, inclusive. The reporting person undertakes to provide to TARA, any security holder of TARA, or the staff of the SEC, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote.

Key Figures

Shares sold: 22,598 shares Weighted average sale price: $5.26 per share Post-transaction holdings: 95,961 shares +2 more

5 metrics

Shares sold 22,598 shares Open-market sale of common stock

Weighted average sale price $5.26 per share Price for sold common shares

Post-transaction holdings 95,961 shares Direct ownership after sale

Sale price range $5.25–$5.31 per share Range of prices across trade executions

10b5-1 plan date December 31, 2025 Date trading plan was established

Key Terms

Rule 10b5-1 trading plan, weighted average price, open-market sale

3 terms

Rule 10b5-1 trading plan regulatory

"occurred automatically pursuant to a Rule 10b5-1 trading plan established by the reporting person on December 31, 2025"

A Rule 10b5-1 trading plan is a pre-arranged schedule that allows company insiders to buy or sell stock at specific times, even if they have inside information. It helps prevent accusations of unfair trading by making these transactions look planned and transparent, rather than sneaky or illegal.

weighted average price financial

"The price reported in Column 4 is a weighted average price"

Weighted average price is the average price of a security where each trade or component is counted according to its size, so bigger trades pull the average more than smaller ones. Think of it like calculating the average cost of a grocery haul where items you bought more of have greater influence on the final per-item cost. Investors use it to understand the true average price paid or received, judge execution quality, and compare trading performance against market movement.

open-market sale financial

"transaction_action": "open-market sale""

An open-market sale is when a shareholder sells existing shares directly on a public exchange to any willing buyer, rather than through a private deal. Think of it like putting goods on a busy market stall where price is set by supply and demand; for investors it matters because such sales increase available supply, can put short-term downward pressure on the stock price, and signal changes in liquidity or investor confidence.

Form 4 Insider Transactions: What Each Field Means →

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Zummo Jacqueline

(Last) (First) (Middle)

C/O PROTARA THERAPEUTICS, INC.

345 PARK AVENUE SOUTH, 3RD FLOOR

(Street)

NEW YORK NEW YORK 10010

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
Protara Therapeutics, Inc. [ TARA ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	Chief R&D Officer

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
04/01/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	04/01/2026		S		22,598(1)	D	$5.26(2)	95,961	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. The sale reported on this Form 4 occurred automatically pursuant to a Rule 10b5-1 trading plan established by the reporting person on December 31, 2025.

2. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $5.25 to $5.31, inclusive. The reporting person undertakes to provide to TARA, any security holder of TARA, or the staff of the SEC, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote.

Remarks:

	/s/ Jacqueline Zummo	04/02/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)

FAQ

What insider transaction did Protara Therapeutics (TARA) report for Jacqueline Zummo?

Protara Therapeutics reported that Chief R&D Officer Jacqueline Zummo sold 22,598 shares of common stock in an open-market transaction at a weighted average price of $5.26 per share. Following the sale, she directly owns 95,961 Protara shares.

Was the Protara Therapeutics (TARA) insider sale made under a Rule 10b5-1 plan?

Yes. The sale was executed automatically under a Rule 10b5-1 trading plan that Jacqueline Zummo established on December 31, 2025. Such pre-arranged plans allow insiders to sell shares on a set schedule, reducing discretion over transaction timing.

At what prices did the Protara Therapeutics (TARA) insider shares sell?

The weighted average sale price was $5.26 per share. According to the disclosure, the 22,598 shares were sold in multiple transactions at prices ranging from $5.25 to $5.31 per share, inclusive, across the executed trades.

How many Protara Therapeutics (TARA) shares does Jacqueline Zummo hold after the sale?

After the reported transaction, Chief R&D Officer Jacqueline Zummo directly holds 95,961 shares of Protara Therapeutics common stock. This figure reflects her position immediately following the 22,598-share open-market sale disclosed in the Form 4 filing.

How many Protara Therapeutics (TARA) shares were sold in this insider transaction?

The Form 4 shows that 22,598 shares of Protara Therapeutics common stock were sold. These sales occurred in the open market at a weighted average price of $5.26 per share, with individual trade prices ranging from $5.25 to $5.31.